ALNOV — Novacyt SA Share Price
Last trade - 00:00- €41.87m
- -€53.30m
- £21.04m
- 27
- 35
- 37
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.3 | ||
| PEG Ratio (f) | 0.22 | ||
| EPS Growth (f) | 11.97% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.33 | ||
| Price to Tang. Book | 0.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.25% | ||
| Return on Equity | -21.08% | ||
| Operating Margin | -293.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 12.14 | 11.47 | 277.2 | 92.6 | 21.04 | 4,700 | 7,130.6 | 13.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +11.97 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.
Directors
- James Wakefield NEC
- David Allmond CEO (51)
- James McCarthy CFO
- Trevor Reginald CTO
- Anthony Dyer EDR
- Mandy Cowling DIR
- Paul Eros EXB
- Steve Gibson EXB
- Lisa Henriet EXB
- Navin Nauth-Misir EXB
- Guillermo Raimondo EXB
- Jean-Pierre Crinelli NED (70)
- Andrew Heath NID
- Edwin Snape NID (81)
- Juliet Thompson NID
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- July 3rd, 2006
- Public Since
- October 12th, 2012
- No. of Employees
- 222
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 70,609,255
- Address
- 13 avenue Morane Saulnier, VELIZY VILLACOUBLAY, 78140
- Web
- https://novacyt.com/
- Phone
- +33 139465104
- Contact
- Mandy Cowling
- Auditors
- Deloitte & Associes
Latest News for ALNOV
Upcoming Events for ALNOV
Full Year 2023 Novacyt SA Earnings Release
Half Year 2024 Novacyt SA Earnings Release
Similar to ALNOV
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
As of Today at 19:15 UTC, shares in Novacyt SA are trading at €0.59. This share price information is delayed by 15 minutes.
Shares in Novacyt SA last closed at €0.59 and the price had moved by -5.2% over the past 365 days. In terms of relative price strength the Novacyt SA share price has underperformed the FTSE Global All Cap Index by -12.55% over the past year.
The overall consensus recommendation for Novacyt SA is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Novacyt SA does not currently pay a dividend.
Novacyt SA does not currently pay a dividend.
Novacyt SA does not currently pay a dividend.
To buy shares in Novacyt SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.59, shares in Novacyt SA had a market capitalisation of €41.87m.
Here are the trading details for Novacyt SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALNOV
Based on an overall assessment of its quality, value and momentum Novacyt SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Novacyt SA is €4.14. That is 597.56% above the last closing price of €0.59.
Analysts covering Novacyt SA currently have a consensus Earnings Per Share (EPS) forecast of £0.20 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novacyt SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -10.29%.
As of the last closing price of €0.59, shares in Novacyt SA were trading -8.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novacyt SA PE ratio based on its reported earnings over the past 12 months is 2.3. The shares last closed at €0.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Novacyt SA's management team is headed by:
- James Wakefield - NEC
- David Allmond - CEO
- James McCarthy - CFO
- Trevor Reginald - CTO
- Anthony Dyer - EDR
- Mandy Cowling - DIR
- Paul Eros - EXB
- Steve Gibson - EXB
- Lisa Henriet - EXB
- Navin Nauth-Misir - EXB
- Guillermo Raimondo - EXB
- Jean-Pierre Crinelli - NED
- Andrew Heath - NID
- Edwin Snape - NID
- Juliet Thompson - NID